Premium Nahrungsergänzungsmittel | artgerecht

FRα (Folate Receptor alpha) – Biomarker and Cancer Target

FRα (Folate Receptor alpha) is a cell-surface protein that binds folate (Vitamin B9) and is overexpressed in many cancers. It serves as a key biomarker and therapeutic target in oncology.

Regular tips about health Regular tips about health

Things worth knowing about "FRα"

FRα (Folate Receptor alpha) is a cell-surface protein that binds folate (Vitamin B9) and is overexpressed in many cancers. It serves as a key biomarker and therapeutic target in oncology.

What is FRα?

FRα stands for Folate Receptor alpha, a glycoprotein expressed on the surface of cells that binds folate (Vitamin B9) with high affinity and facilitates its transport into the cell. While FRα expression is limited in normal healthy tissues, it is significantly overexpressed in a wide range of malignant tumors – particularly ovarian, lung, uterine, and breast cancers. This selective overexpression makes FRα a highly valuable biomarker and therapeutic target in modern oncology.

Biological Function

Folate receptors belong to a family of four structurally related proteins: FRα, FRβ, FRγ, and FRδ. FRα is the most extensively studied member. Its primary physiological role is to capture folate from the bloodstream and transport it into cells, where it is essential for DNA synthesis, cell division, and one-carbon metabolism. In healthy individuals, FRα is mainly expressed in the kidney, placenta, and certain epithelial tissues at low levels.

FRα in Oncology

Overexpression in Cancer

In many solid tumors, FRα is markedly upregulated on the cell surface. High expression rates have been documented in:

Ovarian cancer: FRα positivity in up to 90% of cases
Non-small cell lung cancer (NSCLC), particularly adenocarcinoma
Endometrial (uterine) cancer
Breast cancer, especially triple-negative breast cancer
Carcinomas of the kidney, stomach, and pancreas

FRα as a Biomarker

FRα expression can be detected in tumor tissue using immunohistochemical (IHC) staining. Patients with high FRα expression are considered suitable candidates for targeted therapies that leverage this receptor. Determining FRα status has therefore become an important step in pre-treatment diagnostics and precision oncology workup.

Therapeutic Use of FRα

Antibody-Drug Conjugates (ADCs)

The most clinically advanced therapeutic approach targeting FRα involves antibody-drug conjugates (ADCs). In this strategy, a monoclonal antibody directed against FRα is chemically linked to a cytotoxic payload. Upon binding to FRα on the tumor cell surface, the conjugate is internalized into the cell, where the cytotoxic drug is released to destroy the cancer cell.

A clinically approved example is Mirvetuximab Soravtansine (brand name: Elahere), which has received FDA approval for the treatment of platinum-resistant FRα-positive ovarian cancer.

Other Therapeutic Approaches

Bispecific antibodies: These link FRα on tumor cells with immune effector cells (e.g., T cells) to trigger a targeted immune response against the tumor.
CAR-T cell therapies: Genetically engineered T cells designed to recognize FRα are being investigated for use in solid tumors.
Folate-conjugated nanoparticles: Experimental strategies using folate as a homing ligand to deliver drugs selectively to FRα-expressing tumor cells.

Diagnostics and Testing Methods

FRα is typically detected using the following methods:

Immunohistochemistry (IHC): The most commonly used method. Tumor tissue is stained with a specific anti-FRα antibody and evaluated microscopically for expression level and distribution.
ELISA-based assays: Used to measure soluble FRα in blood serum as a potential circulating biomarker.
Genomic and transcriptomic analysis: Measurement of FRα gene expression (FOLR1 gene) at the mRNA level to complement tumor profiling.

Clinical Significance

The high and selective expression of FRα in specific tumor types, combined with its limited presence in healthy tissue, makes it an ideal target for precision cancer therapy. Determining FRα status enables personalized treatment planning and can significantly improve outcomes for patients with FRα-positive cancers. Research in this field is highly active, with numerous ongoing clinical trials exploring novel FRα-directed therapies.

References

Vergote I, et al. - Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. New England Journal of Medicine, 2022. DOI: 10.1056/NEJMoa2209249
Cheung A, et al. - Targeting Folate Receptor Alpha for Cancer Treatment. Oncogene, 2016. DOI: 10.1038/onc.2015.468
Ledermann JA, et al. - Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Annals of Oncology, 2023.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category